<p>Gyre Therapeutics, Inc.（纳斯达克代码：GYRE - 获取免费报告）首席执行官 Ying Luo 于 5 月 6 日星期三出售了 10,136 股公司股票。股票的平均售价为 8.04 美元，总价值为 81,493.44 美元。交易后，首席执行官持有公司 2,565,226 股股票，价值为 20,624,417.04 美元。此次交易使其持股比例减少了 0.39%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。</p>
<p>获取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
<h2>Gyre Therapeutics 价格表现</h2>
<p>在周四的午盘交易中，Gyre Therapeutics 股票下跌 0.97 美元，达到 7.07 美元。该股票的交易量为 167,488 股，而其平均交易量为 55,514 股。Gyre Therapeutics, Inc. 的一年最低价为 6.57 美元，一年最高价为 11.78 美元。该公司的 50 日移动平均价格为 7.58 美元，200 日移动平均价格为 7.69 美元。该公司的市值为 6.8572 亿美元，市盈率为 707.71，贝塔值为 2.03。</p>
<p>Gyre Therapeutics（纳斯达克代码：GYRE - 获取免费报告）最近于 5 月 7 日星期四发布了季度财报。公司报告本季度每股收益为（0.10 美元），低于分析师共识预期的（0.06 美元）4 美分。该季度的收入为 2252 万美元，而共识预期为 3161 万美元。Gyre Therapeutics 的净利润率为 4.31%，股本回报率为 10.85%。平均而言，股票研究分析师预计 Gyre Therapeutics, Inc. 本财年每股收益将为-0.18 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对 GYRE 股票进行了评估。Wall Street Zen 在 3 月 14 日星期六的报告中将 Gyre Therapeutics 的股票评级从 “买入” 下调至 “持有”。Weiss Ratings 在 1 月 22 日星期四的报告中重新发布了对 Gyre Therapeutics 股票的 “卖出（d）” 评级。最后，Zacks Research 在 3 月 16 日星期一的研究报告中将 Gyre Therapeutics 的评级从 “持有” 下调至 “强烈卖出”。两位股票研究分析师给予该股票 “买入” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 17.00 美元。</p>
<p><strong>查看我们对 Gyre Therapeutics 的最新分析</strong></p>
<h2>机构投资者对 Gyre Therapeutics 的看法</h2>
<p>一些大型投资者最近增持或减持了 GYRE 的股份。Dimensional Fund Advisors LP 在第一季度将其在 Gyre Therapeutics 的持股增加了 131.8%。Dimensional Fund Advisors LP 现在拥有 25,268 股公司股票，价值 176,000 美元，此前在该期间又购买了 14,365 股。纽约梅隆银行在第一季度增持了 Gyre Therapeutics 的股份 4.7%。纽约梅隆银行现在拥有 43,144 股公司股票，价值 301,000 美元，此前在上个季度又收购了 1,941 股。巴克莱银行在第四季度增持了 Gyre Therapeutics 的股份 38.3%。巴克莱银行现在拥有 18,531 股公司股票，价值 131,000 美元，此前在上个季度又收购了 5,135 股。查尔斯·施瓦布投资管理公司在第四季度将其在 Gyre Therapeutics 的持股增加了 37.1%。查尔斯·施瓦布投资管理公司现在拥有 169,158 股公司股票，价值 1,194,000 美元，此前在该期间又收购了 45,772 股。最后，州街公司在第四季度将其在 Gyre Therapeutics 的持股增加了 10.7%。州街公司现在拥有 202,225 股公司股票，价值 1,428,000 美元，此前在该期间又收购了 19,472 股。机构投资者持有该公司 23.99% 的股份。</p>
<h2>关于 Gyre Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Gyre Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于发现和开发小分子疗法，针对脂质生物学以治疗一系列代谢、炎症和神经退行性疾病。该公司的专有平台结合了脂质组学分析与药物发现工具，以识别选择性调节膜脂质组成并恢复疾病相关细胞中正常蛋白功能的化合物。</p>
<p>Gyre 的临床前管线包括非酒精性脂肪性肝炎（NASH）、阿尔茨海默病和自身免疫疾病的项目，反映了其在多个治疗领域应用统一脂质靶向方法的战略。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Gyre Therapeutics</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Gyre Therapeutics 吗？</h2>
<p>在你考虑 Gyre Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Gyre Therapeutics 并不在名单上。</p>
<p>虽然 Gyre Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GYRE

<p>Gyre Therapeutics（纳斯达克代码：GYRE）的首席执行官 Ying Luo 出售了 10,136 股，平均价格为 8.04 美元，总计 81,493.44 美元。出售后，他持有 2,565,226 股，估值约为 2062 万美元，持股比例下降了 0.39%。此次出售已向美国证券交易委员会（SEC）披露。Gyre 的股票最近交易价格为 7.07 美元，市值为 6.8572 亿美元。该公司报告季度每股亏损 0.10 美元，未达到预期。分析师对该股票的评级不一，平均目标价格为 17.00 美元</p>

<p>Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) CEO Ying Luo sold 10,136 shares of the firm's stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total value of $81,493.44. Following the transaction, the chief executive officer owned 2,565,226 shares of the company's stock, valued at $20,624,417.04. The trade was a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink.</p>
<div class="lb-trans"><p>Gyre Therapeutics, Inc.（纳斯达克代码：GYRE - 获取免费报告）首席执行官 Ying Luo 于 5 月 6 日星期三出售了 10,136 股公司股票。股票的平均售价为 8.04 美元，总价值为 81,493.44 美元。交易后，首席执行官持有公司 2,565,226 股股票，价值为 20,624,417.04 美元。此次交易使其持股比例减少了 0.39%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。</p>
</div><p>Get <strong>Gyre Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
</div><h2>Gyre Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 价格表现</h2>
</div><p>Gyre Therapeutics stock traded down $0.97 during mid-day trading on Thursday, reaching $7.07. The stock had a trading volume of 167,488 shares, compared to its average volume of 55,514. Gyre Therapeutics, Inc. has a one year low of $6.57 and a one year high of $11.78. The company has a 50-day moving average price of $7.58 and a two-hundred day moving average price of $7.69. The company has a market capitalization of $685.72 million, a price-to-earnings ratio of 707.71 and a beta of 2.03.</p>
<div class="lb-trans"><p>在周四的午盘交易中，Gyre Therapeutics 股票下跌 0.97 美元，达到 7.07 美元。该股票的交易量为 167,488 股，而其平均交易量为 55,514 股。Gyre Therapeutics, Inc. 的一年最低价为 6.57 美元，一年最高价为 11.78 美元。该公司的 50 日移动平均价格为 7.58 美元，200 日移动平均价格为 7.69 美元。该公司的市值为 6.8572 亿美元，市盈率为 707.71，贝塔值为 2.03。</p>
</div><p>Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.04). The firm had revenue of $22.52 million for the quarter, compared to the consensus estimate of $31.61 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%. On average, equities research analysts anticipate that Gyre Therapeutics, Inc. will post -0.18 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Gyre Therapeutics（纳斯达克代码：GYRE - 获取免费报告）最近于 5 月 7 日星期四发布了季度财报。公司报告本季度每股收益为（0.10 美元），低于分析师共识预期的（0.06 美元）4 美分。该季度的收入为 2252 万美元，而共识预期为 3161 万美元。Gyre Therapeutics 的净利润率为 4.31%，股本回报率为 10.85%。平均而言，股票研究分析师预计 Gyre Therapeutics, Inc. 本财年每股收益将为-0.18 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts recently weighed in on GYRE shares. Wall Street Zen lowered shares of Gyre Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, March 14th. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Finally, Zacks Research cut Gyre Therapeutics from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average price target of $17.00.</p>
<div class="lb-trans"><p>一些股票分析师最近对 GYRE 股票进行了评估。Wall Street Zen 在 3 月 14 日星期六的报告中将 Gyre Therapeutics 的股票评级从 “买入” 下调至 “持有”。Weiss Ratings 在 1 月 22 日星期四的报告中重新发布了对 Gyre Therapeutics 股票的 “卖出（d）” 评级。最后，Zacks Research 在 3 月 16 日星期一的研究报告中将 Gyre Therapeutics 的评级从 “持有” 下调至 “强烈卖出”。两位股票研究分析师给予该股票 “买入” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 17.00 美元。</p>
</div><p><strong>View Our Latest Analysis on Gyre Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Gyre Therapeutics 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Gyre Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Gyre Therapeutics 的看法</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in GYRE. Dimensional Fund Advisors LP lifted its holdings in shares of Gyre Therapeutics by 131.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company's stock valued at $176,000 after buying an additional 14,365 shares during the period. Bank of New York Mellon Corp increased its position in Gyre Therapeutics by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company's stock valued at $301,000 after acquiring an additional 1,941 shares during the last quarter. Barclays PLC increased its position in Gyre Therapeutics by 38.3% during the fourth quarter. Barclays PLC now owns 18,531 shares of the company's stock valued at $131,000 after acquiring an additional 5,135 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company's stock valued at $1,194,000 after acquiring an additional 45,772 shares during the period. Finally, State Street Corp lifted its holdings in Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company's stock valued at $1,428,000 after acquiring an additional 19,472 shares during the period. Institutional investors own 23.99% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近增持或减持了 GYRE 的股份。Dimensional Fund Advisors LP 在第一季度将其在 Gyre Therapeutics 的持股增加了 131.8%。Dimensional Fund Advisors LP 现在拥有 25,268 股公司股票，价值 176,000 美元，此前在该期间又购买了 14,365 股。纽约梅隆银行在第一季度增持了 Gyre Therapeutics 的股份 4.7%。纽约梅隆银行现在拥有 43,144 股公司股票，价值 301,000 美元，此前在上个季度又收购了 1,941 股。巴克莱银行在第四季度增持了 Gyre Therapeutics 的股份 38.3%。巴克莱银行现在拥有 18,531 股公司股票，价值 131,000 美元，此前在上个季度又收购了 5,135 股。查尔斯·施瓦布投资管理公司在第四季度将其在 Gyre Therapeutics 的持股增加了 37.1%。查尔斯·施瓦布投资管理公司现在拥有 169,158 股公司股票，价值 1,194,000 美元，此前在该期间又收购了 45,772 股。最后，州街公司在第四季度将其在 Gyre Therapeutics 的持股增加了 10.7%。州街公司现在拥有 202,225 股公司股票，价值 1,428,000 美元，此前在该期间又收购了 19,472 股。机构投资者持有该公司 23.99% 的股份。</p>
</div><h2>About Gyre Therapeutics</h2>
<div class="lb-trans"><h2>关于 Gyre Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.</p>
<div class="lb-trans"><p>Gyre Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于发现和开发小分子疗法，针对脂质生物学以治疗一系列代谢、炎症和神经退行性疾病。该公司的专有平台结合了脂质组学分析与药物发现工具，以识别选择性调节膜脂质组成并恢复疾病相关细胞中正常蛋白功能的化合物。</p>
</div><p>Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.</p>
<div class="lb-trans"><p>Gyre 的临床前管线包括非酒精性脂肪性肝炎（NASH）、阿尔茨海默病和自身免疫疾病的项目，反映了其在多个治疗领域应用统一脂质靶向方法的战略。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Gyre Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Gyre Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gyre Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Gyre Therapeutics 吗？</h2>
</div><p>Before you consider Gyre Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Gyre Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Gyre Therapeutics 并不在名单上。</p>
</div><p>While Gyre Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Gyre Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

罗英出售了 10,136 股 Gyre Therapeutics（NASDAQ:GYRE）的股票